dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.creatorPenha, Fernando Marcondes [UNIFESP]
dc.creatorRodrigues, Eduardo Buchele [UNIFESP]
dc.creatorMaia, Mauricio [UNIFESP]
dc.creatorFurlani, Bruno de Alburquerque [UNIFESP]
dc.creatorRegatieri, Caio Vinicius Saito [UNIFESP]
dc.creatorMelo, Gustavo Barreto de [UNIFESP]
dc.creatorMagalhães, Octaviano [UNIFESP]
dc.creatorManzano, Roberta [UNIFESP]
dc.creatorFarah, Michel Eid [UNIFESP]
dc.date.accessioned2016-01-24T13:59:01Z
dc.date.accessioned2023-09-04T18:28:30Z
dc.date.available2016-01-24T13:59:01Z
dc.date.available2023-09-04T18:28:30Z
dc.date.created2016-01-24T13:59:01Z
dc.date.issued2010-01-01
dc.identifierOphthalmic Research. Basel: Karger, v. 44, n. 4, p. 205-224, 2010.
dc.identifier0030-3747
dc.identifierhttp://repositorio.unifesp.br/handle/11600/32037
dc.identifier10.1159/000316695
dc.identifierWOS:000280932000001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8615106
dc.description.abstractAims: Retinal pharmacotherapy has gained great importance for the treatment of various retinal diseases. An increasing number of drugs have been constantly released into the market, especially for wet age-related macular disease and diabetic macular edema. in this review, the issues concerning the toxicity of current and new classes of drugs are discussed. Methods: An extensive search of the literature was performed to review various aspects of drug toxicity in retinal pharmacotherapy. the different major classes of drugs, such as corticosteroids, antibiotics, antimetabolites, antineoplastic agents, monoclonal antibodies (mAbs), nonsteroidal anti-inflammatory drugs, enzymes, fibrinolytics, miscellaneous anti-inflammatory and antiangiogenic agents, as well as toxicity unrelated to the drug were identified and discussed. Results: Corticosteroids like fluocinolone, dexamethasone or triamcinolone at low dose cause little damage to the retina, but at high doses signs of toxicity have been well documented. Complications like cataract and glaucoma are quite common with corticosteroids. Aminoglycosides showed differences in the type and doses associated with toxic reactions, thereby the following order of toxicity can be described (from most toxic to least toxic): gentamicin > netilmicin = tobramycin > amikacin = kanamycin. Vancomycin at the usual dose of 1 mg is not toxic to the retina, while further studies are necessary in order to clarify the safety of new-generation quinolones. 5-Fluorouracil has been shown to be nontoxic to the retina after an injection of 2.5 mg in animals. mAbs like ranibizumab and bevacizumab were demonstrated to be safe to the retina in cell culture, animals and humans at high doses. the exact biocompatibility of nonsteroidal anti-inflammatory agents like diclofenac needs further evaluation. Preservatives like benzyl alcohol and changes in pH or osmolarity exert an influence on the toxic effects of intravitreally applied drugs. Conclusions: A great number of drugs are now used mainly intravitreally without relevant retinal toxicity. Copyright (C) 2010 S. Karger AG, Basel
dc.languageeng
dc.publisherKarger
dc.relationOphthalmic Research
dc.rightshttp://www.karger.com/Services/RightsPermissions
dc.rightsAcesso aberto
dc.subjectAvastin
dc.subjectLucentis
dc.subjectRetina
dc.subjectBevacizumab
dc.subjectRanibizumab
dc.subjectMonoclonal antibodies
dc.subjectTumor necrosis factor
dc.subjectVascular endothelial growth factor
dc.subjectCorticosteroids
dc.subjectAntimetabolites
dc.subjectTriamcinolone
dc.subjectNonsteroidal anti-inflammatory drugs
dc.subjectMicroplasmin
dc.titleRetinal and Ocular Toxicity in Ocular Application of Drugs and Chemicals - Part II: Retinal Toxicity of Current and New Drugs
dc.typeResenha


Este ítem pertenece a la siguiente institución